keyword
MENU ▼
Read by QxMD icon Read
search

managment tnbc

keyword
https://www.readbyqxmd.com/read/29753129/applications-of-rna-indexes-for-precision-oncology-in-breast-cancer
#1
REVIEW
Liming Ma, Zirui Liang, Hui Zhou, Lianghu Qu
Precision oncology aims to offer the most appropriate treatments to cancer patients mainly based on their individual genetic information. Genomics has provided numerous valuable data on driver mutations and risk loci; however, it remains a formidable challenge to transform these data into therapeutic agents. Transcriptomics describes the multifarious expression patterns of both mRNAs and non-coding RNAs (ncRNAs), which facilitates the deciphering of genomic codes. In this review, we take breast cancer as an example to demonstrate the applications of these rich RNA resources in precision medicine exploration...
May 9, 2018: Genomics, Proteomics & Bioinformatics
https://www.readbyqxmd.com/read/29752686/the-histone-deacetylase-inhibitor-obp-801-and-eribulin-synergistically-inhibit-the-growth-of-triple-negative-breast-cancer-cells-with-the-suppression-of-survivin-bcl-xl-and-the-mapk-pathway
#2
Hisako Ono, Yoshihiro Sowa, Mano Horinaka, Yosuke Iizumi, Motoki Watanabe, Mie Morita, Emi Nishimoto, Tetsuya Taguchi, Toshiyuki Sakai
PURPOSE: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Eribulin was approved for the treatment of metastatic breast cancer through the EMBRACE trial, and a subgroup analysis in this clinical trial indicated the efficacy of eribulin in patients with TNBC. However, the prognosis of patients with TNBC is still poor due to various molecular characteristics. Therefore, there is an urgent need for a more effective treatment for the management of TNBC...
May 11, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29744672/efficacy-and-safety-of-neoadjuvant-treatment-with-bevacizumab-liposomal-doxorubicin-cyclophosphamide-and-paclitaxel-combination-in-locally-regionally-advanced-her2-negative-grade-iii-at-premenopausal-status-breast-cancer-a-phase-ii-study
#3
Ekaterini C Tampaki, Athanasios Tampakis, Constantinos E Alifieris, Dimitrios Krikelis, Anastasia Pazaiti, Michalis Kontos, Dimitrios T Trafalis
BACKGROUND: In the era of personalized therapy, targeted treatment in specific patient populations is mandated. OBJECTIVE: We evaluated the efficacy and safety of neoadjuvant treatment on locally advanced breast cancer (LABC) with a monoclonal agent against vascular endothelial growth factor (VEGF), bevacizumab plus chemotherapy combination of liposomal doxorubicin, cyclophosphamide and paclitaxel (PLAC-B). METHODS: Patients enrolled were at premenopausal status and characterized by human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor positive (estrogen receptor/progesterone receptor-positive [ER/PR+]) or triple-negative (TNBC), LABC (T > 3 cm), with high-grade ductal carcinoma...
May 9, 2018: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29721479/practical-consensus-recommendations-on-management-of-triple-negative-metastatic-breast-cancer
#4
R Rangarao, B K Smruti, K Singh, A Gupta, S Batra, R K Choudhary, A Gupta, S Sahani, Vedant Kabra, Purvish M Parikh, S Aggarwal
Patients with breast cancer along with metastatic estrogen and progesterone receptor (ER/PR)- and human epidermal growth factor receptor 2 (HER2)-negative tumors are referred to as having metastatic triple-negative breast cancer (mTNBC) disease. Resistance to current standard therapies such as anthracyclines or taxanes limits the available options for previously treated patients with metastatic TNBC to a small number of non-cross-resistant regimens, and there is currently no preferred standard chemotherapy...
April 2018: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/29713831/checkpoint-inhibitors-in-the-treatment-of-breast-cancer
#5
REVIEW
Tomas G Lyons, Maura N Dickler, Elizabeth E Comen
PURPOSE OF REVIEW: The treatment landscape for many cancers has dramatically changed with the development of checkpoint inhibitors. This article will review the literature concerning the use of checkpoint inhibitors in breast cancer. RECENT FINDINGS: The histological subtype of BC with the strongest signal of efficacy has been triple-negative breast cancer (TNBC). Early trials of single-agent checkpoint inhibitors did not demonstrate a uniformly positive signal...
April 30, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29713164/global-trends-in-nanomedicine-research-on-triple-negative-breast-cancer-a-bibliometric-analysis
#6
REVIEW
Ramon Handerson Gomes Teles, Herick Fernando Moralles, Márcia Regina Cominetti
Nanotechnology has emerged as a promising tool in the clinic to combat several difficult-to-manage diseases, such as cancer, which is the second leading cause of death worldwide. Chemotherapeutic drugs present several limitations such as undesired side effects, low specificity, resistance, and high relapse rates. Triple negative breast cancer (TNBC) is caused by cells that lack specific receptors in their membrane, such as estrogen (ER+) and progesterone (PR+) receptors, or by cells that do not express the amplification of human epidermal growth factor receptor-2 (HER-2+)...
2018: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29498411/rsk1-promotes-murine-breast-cancer-growth-and-metastasis
#7
Dominika Czaplinska, Monika Gorska, Kamil Mieczkowski, Grazyna Peszynska-Sularz, Anna J Zaczek, Hanna M Romanska, Rafal Sadej
INTRODUCTION: Triple-negative breast cancer (TNBC), representing over 15% of all breast cancers, has a poorer prognosis than other subtypes. There is no effective targeted treatment available for the TNBC sufferers. Ribosomal S6 kinases (RSKs) have been previously proposed as drug targets for TNBC based on observations that 85% of these tumors express activated RSKs. MATERIALS AND METHODS: Herein we examined an involvement of RSK1 (p90 ribosomal S6 kinase 1) in a regulation of TNBC growth and metastatic spread in an animal model, which closely imitates human disease...
2018: Folia Histochemica et Cytobiologica
https://www.readbyqxmd.com/read/29465744/baseline-factors-predicting-a-response-to-neoadjuvant-chemotherapy-with-implications-for-non-surgical-management-of-triple-negative-breast-cancer
#8
R F D van la Parra, A B Tadros, C M Checka, G M Rauch, A Lucci, B D Smith, S Krishnamurthy, V Valero, W T Yang, H M Kuerer
BACKGROUND: Patients with triple-negative breast cancer (TNBC) and a pathological complete response (pCR) after neoadjuvant chemotherapy may be suitable for non-surgical management. The goal of this study was to identify baseline clinicopathological variables that are associated with residual disease, and to evaluate the effect of neoadjuvant chemotherapy on both the invasive and ductal carcinoma in situ (DCIS) components in TNBC. METHODS: Patients with TNBC treated with neoadjuvant chemotherapy followed by surgical resection were identified...
April 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29458237/randomized-open-label-phase-iii-trial-of-irinotecan-plus-capecitabine-versus-capecitabine-monotherapy-in-patients-with-metastatic-breast-cancer-previously-treated-with-anthracycline-and-taxane-proceed-trial-kcsg-br-11-01
#9
In Hae Park, Seock-Ah Im, Kyung Hae Jung, Joo Hyuk Sohn, Yeon Hee Park, Keun Seok Lee, Sung Hoon Sim, Kyong-Hwa Park, Jee Hyun Kim, Byung Ho Nam, Hee-Jun Kim, Tae-Yong Kim, Kyung-Hun Lee, Sung-Bae Kim, Jin-Hee Ahn, Suee Lee, Jungsil Ro
Purpose: We investigated whether irinotecan plus capecitabine improved progression-free survival (PFS) compared with capecitabine alone in patients with human epidermal growth factor 2 (HER2) negative and anthracycline and taxane pretreated metastatic breast cancer (MBC). Materials and Methods: A total of 221 patients were randomly assigned to irinotecan (80 mg/m2, days 1 and 8) and capecitabine (1,000 mg/m2 twice a day, days 1-14) or capecitabine alone (1,250 mg/m2 twice a day, days 1-14) every 3 weeks...
February 14, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/29435805/kallikrein-related-peptidase-6-klk6-expression-differentiates-tumor-subtypes-and-predicts-clinical-outcome-in-breast-cancer-patients
#10
Christoforos Haritos, Kleita Michaelidou, Konstantinos Mavridis, Ioannis Missitzis, Alexandros Ardavanis, John Griniatsos, Andreas Scorilas
Novel molecular markers that address the heterogeneity of breast cancer (BC) and provide meaningful prognostic information for BC patients are needed. Kallikrein-related peptidase 6 (KLK6) is aberrantly expressed and functionally implicated in BC and, like other members of the KLK family, may prove a useful molecular tool for clinical management. Our objective was to assess, for the first time, the clinical relevance of KLK6 mRNA expression in BC. Total RNA was isolated from 165 breast tumors, as well as 100 adjacent non-cancerous tumor specimens...
May 2018: Clinical and Experimental Medicine
https://www.readbyqxmd.com/read/29391830/neoadjuvant-treatments-in-triple-negative-breast-cancer-patients-where-we-are-now-and-where-we-are-going
#11
REVIEW
Claudia Omarini, Giorgia Guaitoli, Stefania Pipitone, Luca Moscetti, Laura Cortesi, Stefano Cascinu, Federico Piacentini
Triple-negative breast cancer (TNBC) remains the poorest-prognosis breast cancer (BC) subtype. Gene expression profiling has identified at least six different triple-negative subtypes with different biology and sensitivity to therapies. The heterogeneous nature of TN tumors may justify the difficulty in treating this BC subtype. Several targeted agents have been investigated in clinical trials without demonstrating a clear survival benefit. Therefore, systemic chemotherapy remains the cornerstone of current clinical practice...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29373180/immunotherapy-an-evolving-approach-for-the-management-of-triple-negative-breast-cancer-converting-non-responders-to-responders
#12
REVIEW
Mai F Tolba, Hany A Omar
Immunotherapy comprises a promising new era in cancer therapy. Immune checkpoint inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were first approved by the Food and Drug Administration (FDA) for the management of metastatic melanoma in 2011. The approval of this class is being extended to include other types of immunogenic tumors. Although breast cancer (BC) was first categorized as non-immunogenic tumor type, there are certain subsets of BC that showed a high level of tumor infiltrating lymphocytes (TILs)...
February 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29360614/impact-of-multigene-panel-testing-on-surgical-decision-making-in-breast-cancer-patients
#13
Holly J Pederson, Dharmesh Gopalakrishnan, Ryan Noss, Courtney Yanda, Charis Eng, Stephen R Grobmyer
BACKGROUND: With the advent of multigene panel testing for breast cancer patients, germline mutations with unknown association with cancer risk, known as variants of uncertain significance (VUS), are being increasingly identified. Some studies have shown higher rates of contralateral prophylactic mastectomies (CPM) in these patients, despite lack of evidence to support this intervention. We analyzed surgical choices in patients who were identified to have VUS. STUDY DESIGN: A retrospective review was performed of patients with triple-negative breast cancer treated at a single institution after multigene panel tests became available (September 1, 2013 to February 28, 2017)...
April 2018: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/29310608/epoxyazadiradione-suppresses-breast-tumor-growth-through-mitochondrial-depolarization-and-caspase-dependent-apoptosis-by-targeting-pi3k-akt-pathway
#14
Dhiraj Kumar, Saikat Haldar, Mahadeo Gorain, Santosh Kumar, Fayaj A Mulani, Amit S Yadav, Lucio Miele, Hirekodathakallu V Thulasiram, Gopal C Kundu
BACKGROUND: Breast cancer is one of the most commonly diagnosed invasive cancers among women around the world. Among several subtypes, triple negative breast cancer (TNBC) is highly aggressive and chemoresistant. Treatment of TNBC patients has been challenging due to heterogeneity and devoid of well-defined molecular targets. Thus, identification of novel effective and selective agents against TNBC is essential. METHODS: We used epoxyazadiradione to assess the cell viability, mitochondrial potential, ROS level, cell migration, apoptosis and protein expression in cell culture models of TNBC MDA-MB-231 and ER+ MCF-7 breast cancer cells...
January 8, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29285353/triple-negative-breast-cancer-and-its-association-with-obesity
#15
Heng Sun, Jing Zou, Ling Chen, Xuyu Zu, Gebo Wen, Jing Zhong
Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks expression of the estrogen and progesterone receptor and does not overexpress human epidermal growth factor 2 receptor protein. TNBC is associated with special characteristics, including aggressiveness, poor prognosis and poor response to treatment, and has been attracting increasing attention worldwide. Obesity is a well-documented factor exerting a significant effect on the development of breast cancer, including TNBC. The purpose of the present review was to focus on the association between obesity and TNBC and provide a summary of novel research findings...
December 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29249020/multi-omic-approach-decodes-paradoxes-of-the-triple-negative-breast-cancer-lessons-for-predictive-preventive-and-personalised-medicine
#16
Olga Golubnitschaja, Nora Filep, Kristina Yeghiazaryan, Henricus Johannes Blom, Martin Hofmann-Apitius, Walther Kuhn
Breast cancer epidemic in the early twenty-first century results in around two million new cases and half-a-million of the disease-related deaths registered annually worldwide. A particularly dramatic situation is attributed to some specific patient subgroups such as the triple-negative breast cancer (TNBC). TNBC is a particularly aggressive type of breast cancer lacking clear diagnostic approach and targeted therapies. Consequently, more than 50% of the TNBC patients die of the metastatic BC within the first 6 months of the diagnosis...
April 2018: Amino Acids
https://www.readbyqxmd.com/read/29235566/long-term-survival-outcomes-of-triple-receptor-negative-breast-cancer-survivors-who-are-disease-free-at-5-years-and-relationship-with-low-hormone-receptor-positivity
#17
S M Reddy, C H Barcenas, A K Sinha, L Hsu, S L Moulder, D Tripathy, G N Hortobagyi, V Valero
BACKGROUND: We counsel our triple-negative breast cancer (TNBC) patients that the risk of recurrence is highest in the first 5 years after diagnosis. However, there are limited data with extended follow-up on the frequency, characteristics, and predictors of late events. METHODS: We queried the MD Anderson Breast Cancer Management System database to identify patients with stage I-III TNBC who were disease free at 5 years from diagnosis. The Kaplan-Meier method was used to estimate yearly recurrence-free interval (RFI), recurrence-free survival (RFS), and distant relapse-free survival (DRFS), as defined by the STEEP criteria...
January 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29191181/immunohistochemistry-defined-subtypes-of-breast-cancer-in-678-sudanese-and-eritrean-women-hospitals-based-case-series
#18
Asmerom Tesfamariam Sengal, Nada Suliman Haj-Mukhtar, Ahmed Mohammed Elhaj, Shahinaz Bedri, Eva Johanna Kantelhardt, Ahmed A Mohamedani
BACKGROUND: Breast cancer is the most common malignancy accounting for 25% of all cancers in females. In Africa, breast cancer prevalence and mortality are steadily increasing. Knowledge of hormone receptors and human epidermal growth factor receptor-2 (HER-2) expressions are vital for breast cancer management plans and decision making. There is wide regional variation in the proportion of these biomarkers, especially in African countries. Hormone receptors positivity in indigenous African and African American women is considered to be low and triple negative breast cancer is a dominant phenotype...
December 1, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29138528/the-predictive-value-of-pitx2-dna-methylation-for-high-risk-breast-cancer-therapy-current-guidelines-medical-needs-and-challenges
#19
REVIEW
Michaela Aubele, Manfred Schmitt, Rudolf Napieralski, Stefan Paepke, Johannes Ettl, Magdalena Absmaier, Viktor Magdolen, John Martens, John A Foekens, Olaf G Wilhelm, Marion Kiechle
High-risk breast cancer comprises distinct tumor entities such as triple-negative breast cancer (TNBC) which is characterized by lack of estrogen (ER) and progesterone (PR) and the HER2 receptor and breast malignancies which have spread to more than three lymph nodes. For such patients, current (inter)national guidelines recommend anthracycline-based chemotherapy as the standard of care, but not all patients do equally benefit from such a chemotherapy. To further improve therapy decision-making, predictive biomarkers are of high, so far unmet, medical need...
2017: Disease Markers
https://www.readbyqxmd.com/read/29082597/magnetic-resonance-molecular-imaging-of-metastatic-breast-cancer-by-targeting-extradomain-b-fibronectin-in-the-tumor-microenvironment
#20
Zheng Han, Han Cheng, Jenny G Parvani, Zhuxian Zhou, Zheng-Rong Lu
PURPOSE: Non-invasive early accurate detection of malignant breast cancer is paramount to the clinical management of the life-threatening disease. Here, we aim to test a small peptide targeted MRI contrast agent, ZD2-Gd(HP-DO3A), specific to an oncoprotein, extradomain-B fibronectin (EDB-FN), in the tumor microenvironment for MR molecular imaging of breast cancer. METHOD: EDB-FN expression in 4T1 and MDA-MB-231 cancers was analyzed with quantitative real-time PCR and western blot...
June 2018: Magnetic Resonance in Medicine: Official Journal of the Society of Magnetic Resonance in Medicine
keyword
keyword
55830
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"